High PD-L1 expression is associated with a poor prognosis in various malignant tumors (15, 16); blockades targeting the PD-1/PD-L1 pathway have shown controllable safety and durable remissions in lung cancer, melanoma, bladder cancer, and other tumors (17–28). This evidence concerns the gene CD274 and urinary bladder carcinoma.